Core Insights - DeepMind's AlphaGenome can decode 98% of human genetic "dark matter" with an accuracy of 90% [3][5] - The model predicts 11 different gene regulatory processes and analyzes complex gene splicing mechanisms [5] - AlphaGenome processes over 1 million API calls daily, with over 3,000 users across 160 countries [5] Industry Implications - AI's role in drug development is expected to enhance efficiency significantly, with McKinsey predicting a 35% to 45% increase in clinical development efficiency over the next five years [6] - Major pharmaceutical companies like Eli Lilly, AstraZeneca, Novartis, and Pfizer are investing heavily in AI for drug discovery [6] - Analysts suggest that while AI applications in pharmaceuticals are widespread, it may take one to three years for investors to see returns from accelerated drug development [6] Future Outlook - DeepMind's CEO predicts that AI will be able to cure all diseases within the next decade [5] - The latest version of AlphaFold has accurately predicted 98.5% of human protein structures, indicating a significant advancement in biological research [6] - Clinical trials for AI-designed drugs are anticipated to begin soon, marking a new phase in pharmaceutical innovation [6]